Juncell Therapeutics is focused on innovative TIL (tumor-infiltrating lymphocyte) therapies for solid tumors, including both natural TIL programs and non-viral gene-modified TIL programs. Our TIL therapies are featured with an improved safety profile without compromising efficacy, thanks to the enhanced TIL manufactured by DeepTIL® cell expansion platform. DeepTIL® enables TIL to be potent enough so that the high-dose IL-2 combination could be eliminated and the intensity of pretreatment could be much lower. Juncell also established the NovaGMP® non-viral vector gene-modification platform, which is of high efficiency (> 45% in the final cell product) and low cost of goods (<10% of lentiviral vector). Juncell natural TIL therapy GC101 and gene-engineered TIL therapy GC203 have shown promising efficacy in melanoma, lung cancer, ovarian cancer, pancreatic cancer, cervical cancer, endometrial cancer, bile duct cancer, glioma and breast cancer.

Juncell Therapeutics

Org chart

Teams

Offices

Juncell Therapeutics

Org chart

Teams

Offices

Related companies